THE COLOR OF CLINICAL TRIALS: A TIMELINE BASED ON PHARMACEUTICAL ETHICS

Abstract

The weight of the black community in the expansion of new health technologies is considered unequal and inferior in comparison to the weight of the white population's participation. This study orders a reflective process of the place where the black population is inserted in pharmaceutical ethical guidelines in the context of clinical trials today, in contrast to past eras. According to the bibliographies used in this article, participation is compromised even in pathological situations in which the black community may be the most affected. It is therefore necessary to ensure that the black community is included in ethical-social trials and to develop anti-racist strategies to occupy a space that is still little observed in the participatory context and in the contribution of ethnic-social diversity in innovative public health technologies, as well as bringing historical facts to the present day to reflect on how circumstances in the past were shaped based on outdated scientific etymologies that were thought up according to the strands of racism and its faces. This racism brings to light a situation based on ethnic hierarchy, which places the white community in a position of privilege and the black community in a position of subalternity. This literature review also portrays the most emblematic historical facts about the use of the black population for scientific advances in the past, how these events affect the population and sculpt scientific racism, and brings up possible measures that the pharmaceutical industries, institutes and organizations that promote clinical trials can put into action in order to guarantee an ethnically diverse representation in clinical trials for the development of new health technologies.